For: | Rosen I, Kori M, Adiv OE, Yerushalmi B, Zion N, Shaoul R. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C. World J Gastroenterol 2013; 19(7): 1098-1103 [PMID: 23467199 DOI: 10.3748/wjg.v19.i7.1098] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v19/i7/1098.htm |
Number | Citing Articles |
1 |
Hitoshi Tajiri, Kazuhiko Bessho, Yoshiko Nakayama, Daiki Abukawa, Yoshinori Iitsuka, Yoshinori Ito, Ayano Inui, Yuri Etani, Mitsuyoshi Suzuki, Tomoko Takano, Atsushi Tanaka, Tatsuki Mizuochi, Yoko Miyoshi, Jun Murakami. Clinical practice guidelines for the management of children with mother‐to‐child transmitted hepatitis C virus infection. Pediatrics International 2022; 64(1) doi: 10.1111/ped.14962
|
2 |
|
3 |
Leigh Cervino, Lauren M. Hynicka. Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?. Annals of Pharmacotherapy 2018; 52(11): 1152 doi: 10.1177/1060028018772181
|
4 |
A. El Sherbini, S. Mostafa, E. Ali. Systematic review with meta‐analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2015; 42(1): 12 doi: 10.1111/apt.13221
|
5 |
Wenya Shan, Dongsheng Hong, Jieqiang Zhu, Qingwei Zhao. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy. Computational and Mathematical Methods in Medicine 2020; 2020: 1 doi: 10.1155/2020/1391583
|
6 |
Juan Francisco Sánchez-Ávila. Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. Annals of Hepatology 2015; 14: S7 doi: 10.1016/S1665-2681(19)30815-4
|